Published: Apr 05, 2021
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE)
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its presence at the National Kidney Foundation’s 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021.
As a leader in non-invasive approaches for assessing the health of transplanted kidneys, CareDx will host
“Next Generation Care for Kidney Transplant Patients,” a 30-minute exhibitor showcase on April 6th from 11:00-11:30 a.m. Eastern Time.
Program details:
Innovations in Kidney Transplant Care, with Dr. Christopher Boshkos, Medical Director of Kidney Transplantation at CareDx
Published: Apr 05, 2021
CAMBRIDGE, Mass. (BUSINESS WIRE) ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, today announced that Annalisa D’Andrea, Ph.D., has been appointed President and Chief Scientific Officer. Dr. D’Andrea brings more than 25 years of experience in translational research in immunology to ImmuneID.
“The addition of Annalisa as President and CSO is an important milestone for ImmuneID, as the company applies its platform to identify promising immunological therapeutic targets,” said Stephen Elledge, Ph.D., ImmuneID co-founder and Chair of ImmuneID SAB, Lasker Award winner, and The Gregor Mendel Professor of Genetics and Medicine, Harvard Medical School. “Annalisa’s experience advancing drug candidates to the clinic will be extremely valuable and I look forward to working with her.”
Published: Apr 05, 2021
BRIDGEWATER, N.J. (BUSINESS WIRE) Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE: AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced that Amneal Pharmaceuticals LLC (“Amneal”), a subsidiary of the Company, has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.
“We are very pleased to announce the completion of this transaction. Through the acquisition of Kashiv Specialty Pharma, Amneal has gained an exciting pipeline of both 505(b)2 branded products and complex generics. Perhaps most importantly, we are adding a team of world class R&D scientists with a proven track record of developing complex generic products (e.g. Yuvafem and EluRyng), as well as a platform of innovative drug delivery technologies. T
Published: Mar 29, 2021
NEW YORK and PERTH, Australia, March 29, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Jason Haddock to its Board of Directors. Mr. Haddock brings more than two decades of financial, commercial and operational leadership experience in the biopharmaceutical industry, and currently serves as a Board Director of Codiak BioSciences, a biotech company developing precision exosome therapeutics.
Throughout his career, Mr. Haddock has held a variety of leadership roles at biopharma companies, overseeing finance, commercial and business development strategies in the U.S. and worldwide. Previously, he was Chief Financial Officer at Array Biopharma, where he was instrumental in developing a research, development and commercialization strategy that culminated in the successful launch an
Published: Apr 01, 2021
Unwavering R&D initiatives is compelling government entities to sanction research projects incorporating advanced genetic analyzer systems
Fact.MR, Rockville MD: The ongoing study on genetic analyzer systems market being conducted by Fact.MR forecasts an optimistic outlook through 2021 and beyond. The novel coronavirus pandemic provided additional tailwinds through FY 2020-21, as healthcare experts were extensively engaged in discovering key breakthroughs to combat the deadly virus.
Prior to the pandemic’s onset, the market was already posting impressive gains, majorly underpinned by unceasing research initiatives by multiple entities. For instance, the Department of Biotechnology (DBT) in India initiated the Genome India Project (GIP) on 3